ARTICLE SUMMARY:
Conceived in the Stanford Biodesign Program, ENT start-up Spirair offers a breath of fresh air in the treatment of nasal septal deviation.
The prestigious Stanford Biodesign Program has generated variety of innovative technologies and companies over the years, always starting with identifying a clinical need in a given area of medicine. Spirair, led by CEO Ben Bishop, is no exception, targeting nasal septal deviation (NSD) with a minimally invasive, dissolvable implant. Before joining co-founders James Kintzing, PhD, and Brandon McCutcheon, MD, fellows of the Biodesign Program, Bishop spent 20 years in medical device sales and leadership, working with Silicon Valley venture-backed medtech and biotech start-ups since 2007. His experience with disruptive, minimally invasive technologies, working with such companies as Access Closure, Revelle Aesthetics, Revance Therapeutics, and Arrinex, led him to a role on Spirair’s board of directors in 2023, followed by the CEO position in January 2024.
